Shares Of Aerie Pharmaceuticals Drop 70% In After Hours After Reporting Disappointing Phase 3 Results
April 23, 2015 at 21:03 PM EDT
Shares of AERI have dropped by 70% after hours as the company reported that the company's drug Rhopressa failed to meet the primary endpoint in a phase 3 trial.
